Next CRO SYMVOULOI FARMAKEUTIKON EPICHEIRISEON M.E.P.E
Next CRO SYMVOULOI FARMAKEUTIKON EPICHEIRISEON M.E.P.E is recorded as a service provider in 12 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 12 of 12 trials · Latest update first
A Phase 2b, Open-label, Multi-arm Clinical Trial of Selinexor Plus Low-dose Dexamethasone (Sd) in Patients with Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone (SVd) in Patients with Triple-class Refractory Multiple Myeloma
Sponsor Karyopharm Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy (OPUS OLE)
Sponsor Viatris Innovation GmbH
- Start (EU)
- Latest update
- Estimated end
LUMIOS - A Phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to assess the efficacy, safety and tolerability of cenerimod in adult patients with systemic lupus erythematosus and active lupus nephritis in combination with background therapy
Sponsor Viatris Innovation GmbH
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3)
Sponsor Summit Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
COLchicine and non-enteric coated aspirin in the Cardiovascular Outcomes Trial of patients with Type 2 Diabetes (COLCOT-T2D)
Sponsor Montreal Heart Institute
- Start (EU)
- Latest update
- Estimated end
A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction
Sponsor Viatris Innovation GmbH
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
Sponsor Karyopharm Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Comparison of the effectiveness of IntraVenous FLECainide plus oral ranolazine versus intravenous flecainide alone in the cardioversion of recent onset atrial fibrillation - a randomized, prospective, multicentre, open-label study, the IV-FLEC study.
Sponsor Win Medica Pharmaceutical A.E.
- Start (EU)
- Latest update
- Estimated end
- Not reported
OPUS-1 - Oral S1P1 Receptor ModUlation in SLE: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy
Sponsor Viatris Innovation GmbH
- Start (EU)
- Latest update
- Estimated end
A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma [CERPASS]
Sponsor Replimune Group Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer
Sponsor Summit Therapeutics Sub Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Next CRO SYMVOULOI FARMAKEUTIKON EPICHEIRISEON M.E.P.E?
The 2026-10-09 snapshot links Next CRO SYMVOULOI FARMAKEUTIKON EPICHEIRISEON M.E.P.E to 12 distinct CTIS trials. Recorded services include Clinical monitoring, Regulatory services, Investigator recruitment, Project management, among 8 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Next CRO SYMVOULOI FARMAKEUTIKON EPICHEIRISEON M.E.P.E?
The most frequently recorded therapeutic areas are Immunology, Cardiology, Endocrinology, Haematological Malignancies. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Next CRO SYMVOULOI FARMAKEUTIKON EPICHEIRISEON M.E.P.E conducted?
The linked trials record locations in 24 countries, including Greece, Germany, Spain, France, Poland. These are trial locations, not confirmed office locations or countries where Next CRO SYMVOULOI FARMAKEUTIKON EPICHEIRISEON M.E.P.E delivered services.
What can this page tell me about Next CRO SYMVOULOI FARMAKEUTIKON EPICHEIRISEON M.E.P.E's trial experience?
Browse 12 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Next CRO SYMVOULOI FARMAKEUTIKON EPICHEIRISEON M.E.P.E. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Next CRO SYMVOULOI FARMAKEUTIKON EPICHEIRISEON M.E.P.E.